Annual report pursuant to Section 13 and 15(d)

Accrued Liabilities and other Long-Term Liabilities - Components of Accrued Expenses and Other Long-Term Liabilities (Detail)

v3.8.0.1
Accrued Liabilities and other Long-Term Liabilities - Components of Accrued Expenses and Other Long-Term Liabilities (Detail) - USD ($)
$ in Thousands
Dec. 31, 2017
Dec. 31, 2016
Accrued expenses:    
Professional fees $ 1,625 $ 1,253
Salaries, bonuses and related benefits 5,279 2,846
Accrued expenses - related party 95 0
Accrued severance 0 53
Ovamed manufacturing rights - short term component 0 900
Research and development 4,046 394
Dr. Falk Pharma milestone (See Note 16) 3,059 2,634
Accrued royalties payable 1,411 263
Accrued coupon expense 1,087 463
Lease impairment 0 128
Other 1,030 1,148
Total accrued expenses 17,632 10,082
Other long-term liabilities:    
Deferred rent and long-term lease abandonment charge 4,739 5,014
Total other long-term liabilities $ 4,739 $ 5,014